Year-end Sale % OFF 
Abstract
Objective: Surgery is the first line treatment of colorectal cancer (CRC). Anesthetic isoflurane may improve outcomes of cancer surgery. Herein, we investigated the effects of isoflurane on malignant behaviors of CRC cells and its underlying therapeutic target.Methods: SW620 and HCT116 CRC cells were exposed to a series of concentrations of isoflurane. CCK-8 assay was utilized for determination of the optimal concentration of isoflurane. Under treatment with isoflurane, proliferation, migration, and invasion were separately assessed via clone formation and transwell assays. Apoptotic levels were observed via flow cytometry and expression of Bax, Bcl-2, and Caspase3 proteins was quantified through western blot. MiR-216 expression was detected in isoflurane-induced SW620 and HCT116 cells by RT-qPCR. Following transfection with miR-216 mimic, malignant biological behaviors were examined in isoflurane-treated SW620 and HCT116 cells.Results: 40 μM isoflurane distinctly restrained proliferative, migrated, and invasive capacities and elevated apoptotic levels in SW620 and HCT116 cells. Up-regulation of miR-216 was found in CRC cells. Its expression was suppressed by isoflurane. MiR-216 mimic ameliorated the reduction in proliferation, migration, and invasion and the increase in apoptosis for 40 μM isoflurane-induced SW620 and HCT116 cells.Conclusion: Isoflurane, a promising drug of CRC, may suppress malignant biological behaviors of tumor cells. Furthermore, miR-216 is an underlying target of isoflurane. Thus, isoflurane could be adopted for CRC treatment.
Highlights
Colorectal cancer (CRC) becomes the third most common malignant tumor as well as the second major cause of cancer-related deaths [1]
This study further investigated whether isoflurane exposure could affect migration and invasion of CRC cells via miR216
MiR-216 up-regulation was discovered in CRC cells
Summary
Colorectal cancer (CRC) becomes the third most common malignant tumor as well as the second major cause of cancer-related deaths [1]. It was estimated that there were 1,800,977 diagnosed cases and 861,663 death cases globally in 2018 [2]. It has been under expectation that death toll will rise in colon and rectal carcinoma by 60 and 71.5% until 2035 [3]. The incidence of CRC tends to be Isoflurane Suppresses Colorectal Cancer Progression younger [4]. Distant metastases contribute to unfavorable outcomes of CRC patients. CRC therapies often contain surgery, chemotherapy as well as targeted therapy. The therapeutic strategies against CRC remain dissatisfactory. Exploring new drugs and targets is indispensable
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
